Xenon Pharmaceuticals Inc. ( XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation December 10, 2025 10:00 AM EST ...

GLP-1 receptor agonists (GLP-1 RAs) are transforming metabolic disease treatment, with analytical chemists playing a critical role in formulation, stability testing, and clinical trial support for ...

Achieve reliable water content analysis with volumetric KF titration, using advanced techniques for accuracy and ...

Homogenizers are high-speed, high-shear stirrers that efficiently disperse powders and shred a wide range of solids, ...

The executives of the companies say by pairing weight-loss drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro) with ...

A man in his 50s, normally fit and well, had an ischaemic thalamic stroke confirmed on MRI, manifesting with left-sided weakness, numbness and ataxia. Admission BP was 254/150 mm Hg. All tests for ...

Structure Therapeutics recently reported positive topline Phase 2b and related ACCESS program data for its oral GLP-1 agonist aleniglipron in adults with obesity or overweight, showing clinically ...

The December issue of the Journal of Cardiac Failure (JCF), now available, offers a robust lineup of original research, ...

Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...

The 2026 update to the ADA’s Standards of Care in Diabetes introduces new guidance on a wide range of topics, including the ...

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related ...